as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹150.55
Change
-1.16 (-0.76%)
Open
₹152.0
Prev. Close
₹151.71
Day High
₹153.0
Day Low
₹148.41
Volume Analysis
Traded
623,779
Delivered
289,986
Delivery %
46.49%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (25.0%)
Weaknesses (0)
No signal for this stock
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹157.48 | ₹155.24 | ₹152.89 | ₹150.65 | ₹148.3 | ₹146.06 | ₹143.71 |
| Fibonacci | ₹155.24 | ₹153.49 | ₹152.4 | ₹150.65 | ₹148.9 | ₹147.81 | ₹146.06 |
| Camarilla | ₹151.81 | ₹151.39 | ₹150.97 | ₹150.65 | ₹150.13 | ₹149.71 | ₹149.29 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+45.54%
1 Week
-4.03%
1 Month
-18.13%
3 Months
-1.58%
6 Months
+5.08%
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹38.48
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
4.92%
Net margin 15.87% × asset turnover 0.25x × equity multiplier 1.24x
Company Overview
Sector
Healthcare
Market Cap
₹1,269 Cr
P/E (TTM)
66.8
ROE
11.1%
Book Value
₹33.4
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.
TopFund Analysis
Gujarat Kidney N Sup Sp L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 54/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (25.0%). FII holding has been falling.
TopFund Score — Fundamentals Quality
54/100 — AverageData confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is expected to give good quarter
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company has high debtors of 172 days.
- −Working capital days have increased from 55.7 days to 91.1 days
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Newspaper publication for Unaudited Financial Statements for the Quarter ended September 2026.
Audio recording of Q2 FY27 earnings call uploaded on November 5, 2026.
Investor Presentation for scheduled Conference Call on November 05, 2026
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 9 | 12 | 10 | 15 | 13 | 23 | 31 | 34 | 38 |
| Expenses + | 5 | 7 | 7 | 7 | 8 | 16 | 24 | 26 | 28 |
| Operating Profit | 5 | 5 | 3 | 9 | 5 | 7 | 6 | 8 | 10 |
| OPM % | 51.65% | 39.02% | 26.69% | 56.49% | 39.6% | 29.68% | 20.6% | 24.41% | 26.8% |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 |
| Profit before tax | 4 | 4 | 2 | 7 | 4 | 5 | 5 | 7 | 9 |
| Tax % | 26.25% | 29.72% | 16.88% | 27.77% | 28.54% | 26.44% | -2.99% | 23.56% | 23.55% |
| Net Profit + | 3 | 3 | 1 | 5 | 3 | 4 | 5 | 5 | 7 |
| EPS in Rs | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 |
| Raw PDF | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | — | — | — | — | 37 | 97 | 213 | 125 | 195 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| Sales + | 0 | 5 | 40 | 82 | 126 |
| Expenses + | 0 | 3 | 24 | 55 | 94 |
| Operating Profit | 0 | 2 | 17 | 27 | 32 |
| OPM % | — | 41.0% | 41.0% | 33.0% | 25.0% |
| Other Income + | 0 | 1 | 0 | 1 | 2 |
| Interest | 0 | 0 | 1 | 2 | 3 |
| Depreciation | 0 | 0 | 3 | 5 | 6 |
| Profit before tax | 0 | 2 | 13 | 21 | 25 |
| Tax % | 0.0% | 25.0% | 26.0% | 21.0% | — |
| Net Profit + | 0 | 2 | 10 | 17 | 20 |
| EPS in Rs | 0 | 0 | 2 | 2 | 2 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | — | — | 744 | 104 | 154 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|
| Reserves | 0 | 11 | 15 | 237 | 248 |
| Borrowings + | 0 | 6 | 8 | 29 | 30 |
| Other Liabilities + | 4 | 4 | 21 | 16 | 33 |
| Total Liabilities | 4 | 21 | 55 | 298 | 327 |
| Fixed Assets + | 0 | 14 | 31 | 129 | 149 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 12 | 12 |
| Other Assets + | 4 | 7 | 24 | 157 | 165 |
| Total Assets | 4 | 21 | 55 | 298 | 327 |
| Equity Capital | 0 | 0 | 11 | 16 | 16 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | 0 | 1 | 14 | -4 |
| Cash from Investing Activity + | 0 | 0 | -18 | -214 |
| Cash from Financing Activity + | 0 | 0 | 6 | 228 |
| Net Cash Flow | 0 | 1 | 2 | 11 |
| Free Cash Flow | 0 | 2 | -5 | -98 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 0 | 70 | 99 | 21 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|
| Public | 16.4% | 23.1% | 23.1% | 21.77% |
| Promoters | 71.45% | 71.45% | 71.45% | 71.45% |
| FII | 10.47% | 4.89% | 4.89% | 6.52% |
| DII | 1.67% | 0.56% | 0.56% | 0.25% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Gujarat Kidney N Sup Sp L (this stock) | 1,269 | 66.8 | 4.82 | 11.1% |
| Kopran Ltd | 1,281 | 32.6 | 2.44 | 4.91% |
| Shalby Limited | 1,317 | 33.6 | 1.29 | 2.45% |
| Anlon Healthcare Limited | 1,348 | 37.8 | 5.25 | 18.4% |
| Fermenta Biotech Ltd. | 1,367 | 29.4 | 3.27 | 17.3% |
| 3b Blackbio Dx Ltd. | 1,157 | 19.7 | 3.33 | 19.8% |
| Jagsonpal Pharmaceuticals | 1,402 | — | 5.82 | — |
Which Mutual Funds Hold Gujarat Kidney N Sup Sp L?
Frequently Asked Questions about Gujarat Kidney N Sup Sp L
Gujarat Kidney N Sup Sp L (GKSL) closed at ₹150.55 on NSE on 19 November 2026, down 1.16 (0.76%) from the previous close.
Gujarat Kidney N Sup Sp L trades on the NSE (National Stock Exchange of India) under the symbol GKSL.
Gujarat Kidney N Sup Sp L has a trailing twelve-month P/E (price-to-earnings) ratio of 66.8.
Gujarat Kidney N Sup Sp L has a dividend yield of 0.0%.
Gujarat Kidney N Sup Sp L's 52-week high is ₹210.0 and its 52-week low is ₹98.2.
Gujarat Kidney N Sup Sp L has a market capitalisation of ₹1,269 crore.
Gujarat Kidney N Sup Sp L has a TopFund Quality Score of 54/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Gujarat Kidney N Sup Sp L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.